The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis

MeSH terms

• Anti-Obesity Agents / administration & dosage
• Anti-Obesity Agents / adverse effects
• Biopsy / methods
• Body Mass Index
• Diabetes Mellitus, Type 2* / blood
• Diabetes Mellitus, Type 2* / diagnosis
• Diabetes Mellitus, Type 2* / drug therapy
• Dose-Response Relationship, Drug
• Drug Monitoring / methods
• Drug Monitoring / statistics & numerical data
• Female
• Gastrointestinal Agents / administration & dosage
• Gastrointestinal Agents / adverse effects
• Glucagon-Like Peptide-1 Receptor Agonists*
• Glucagon-Like Peptides* / administration & dosage
• Glucagon-Like Peptides* / adverse effects
• Glycated Hemoglobin / analysis
• Humans
• Hypoglycemic Agents / administration & dosage
• Hypoglycemic Agents / adverse effects
• Liver / pathology
• Liver Cirrhosis* / diagnosis
• Liver Cirrhosis* / drug therapy
• Male
• Middle Aged
• Non-alcoholic Fatty Liver Disease* / blood
• Non-alcoholic Fatty Liver Disease* / diagnosis
• Non-alcoholic Fatty Liver Disease* / drug therapy
• Non-alcoholic Fatty Liver Disease* / physiopathology
• Treatment Outcome